Pages that link to "Q30444892"
Jump to navigation
Jump to search
The following pages link to Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. (Q30444892):
Displaying 50 items.
- Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies (Q22305832) (← links)
- Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C (Q24200189) (← links)
- Economic assessment of eltrombopag in the treatment of thrombocytopenia (Q33424436) (← links)
- Outcomes of hepatitis C screening programs targeted at risk groups hidden in the general population: a systematic review (Q33590896) (← links)
- The hepatitis C cascade of care: identifying priorities to improve clinical outcomes (Q33632459) (← links)
- Cost-effectiveness of enhanced liver fibrosis test to assess liver fibrosis in chronic hepatitis C virus and alcoholic liver disease patients. (Q33652027) (← links)
- Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India (Q33698956) (← links)
- The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients (Q33710740) (← links)
- Reasons for compliance or noncompliance with advice to test for hepatitis C via an internet-mediated blood screening service: a qualitative study (Q33898300) (← links)
- Economic burden of hepatitis C-associated diseases in the United States. (Q34253963) (← links)
- Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study (Q34690368) (← links)
- Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs (Q34735072) (← links)
- Cost-effectiveness of IL28Β genotype-guided protease inhibitor triple therapy versus standard of care treatment in patients with hepatitis C genotypes 2 or 3 infection (Q34765761) (← links)
- Is adding HCV screening to the antenatal national screening program in Amsterdam, the Netherlands, cost-effective? (Q34946693) (← links)
- Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C. (Q35011072) (← links)
- Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection. (Q35205389) (← links)
- The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection (Q35572125) (← links)
- Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. (Q35596366) (← links)
- Viral hepatitis C. (Q35617324) (← links)
- Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States (Q35619161) (← links)
- The current economic burden of cirrhosis. (Q35691411) (← links)
- Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany--an application of the efficiency frontier approach (Q35724374) (← links)
- Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. (Q35768976) (← links)
- Management of chronic hepatitis C virus infection: a new era of disease control (Q35823410) (← links)
- Hepatitis C: What is the best treatment? (Q35882861) (← links)
- A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs (Q35889562) (← links)
- Peginterferon-alpha 2a (40 kDa)/ribavirin combination for the treatment of chronic hepatitis C infection (Q35917238) (← links)
- Pegylating IFNs at his-34 improves the in vitro antiviral activity through the JAK/STAT pathway (Q36007339) (← links)
- Chronic hepatitis C virus infection: does it really impact health-related quality of life? A study in rural Egypt (Q36020207) (← links)
- Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation. (Q36057034) (← links)
- Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6. (Q36095525) (← links)
- Cost-Effectiveness of Hepatitis C Treatment for People Who Inject Drugs and the Impact of the Type of Epidemic; Extrapolating from Amsterdam, the Netherlands (Q36155257) (← links)
- Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany (Q36238515) (← links)
- Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach--the case study of Canada (Q36272393) (← links)
- Health state utilities associated with attributes of treatments for hepatitis C. (Q36285092) (← links)
- Pegylated IFNs for chronic hepatitis C: an update (Q36316698) (← links)
- Evaluating the evidence from clinical trials in chronic hepatitis C. (Q36455990) (← links)
- Hepatitis C virus infection down-regulates the expression of peroxisome proliferator-activated receptor alpha and carnitine palmitoyl acyl-CoA transferase 1A. (Q36503299) (← links)
- Health-state utilities in liver disease: a systematic review. (Q37142994) (← links)
- Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States (Q37286544) (← links)
- Treating hepatitis C in the prison population is cost-saving (Q37299503) (← links)
- Review of cost-effectiveness studies of pegylated therapies for hepatitis C. (Q37609421) (← links)
- Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service (Q37682673) (← links)
- A systematic review of the cost-effectiveness of peginterferon alfa-2b in the treatment of chronic hepatitis C. (Q37763117) (← links)
- Review of models used to predict the future numbers of individuals with severe hepatitis C disease: therapeutic and cost implications (Q37763157) (← links)
- Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis. (Q38019467) (← links)
- Hepatitis C virus in Asia: utility values based on the Short Form-36 questionnaire (Q38068462) (← links)
- Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature (Q38206573) (← links)
- Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis (Q39025577) (← links)
- The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States. (Q39137372) (← links)